S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
NASDAQ:HROW

Harrow Health (HROW) Stock Forecast, Price & News

$19.56
+0.05 (+0.26%)
(As of 06/2/2023 ET)
Compare
Today's Range
$19.08
$19.71
50-Day Range
$18.86
$28.08
52-Week Range
$6.00
$28.25
Volume
220,342 shs
Average Volume
626,787 shs
Market Capitalization
$589.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.47

Harrow Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
55.8% Upside
$30.47 Price Target
Short Interest
Bearish
7.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
1,450.00%
From $0.06 to $0.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

364th out of 983 stocks

Pharmaceutical Preparations Industry

173rd out of 486 stocks


HROW stock logo

About Harrow Health (NASDAQ:HROW) Stock

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Stock News Headlines

Harrow Health (NASDAQ:HROW) Shares Down 9%
Harrow Health (NASDAQ:HROW) Trading Down 5%
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
Lake Street Keeps Their Buy Rating on Harrow Health (HROW)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Why Shares of Harrow Health Are Slumping Friday
Harrow Health (NASDAQ:HROW) Hits New 52-Week High at $28.25
Recap: Harrow Health Q1 Earnings
Earnings Preview For Harrow Health
Harrow Health's (HROW) Buy Rating Reaffirmed at B. Riley
Harrow Health, Inc. (NASDAQ:HROW) Short Interest Update
2 Stocks in Focus as Analysts Initiate Coverage
See More Headlines

HROW Price History

HROW Company Calendar

Last Earnings
3/23/2023
Today
6/03/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HROW
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.47
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+55.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,090,000.00
Pretax Margin
-19.99%

Debt

Sales & Book Value

Annual Sales
$88.60 million
Cash Flow
$0.22 per share
Book Value
$0.71 per share

Miscellaneous

Free Float
25,827,000
Market Cap
$589.15 million
Optionable
Optionable
Beta
0.20

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek MBA (Age 62)
    Chief Commercial Officer
    Comp: $621.92k
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Mr. Andrew Livingston
    Chief Innovation Officer
  • Ms. Kim Barratt
    Chief Talent Officer













HROW Stock - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares.
View HROW analyst ratings
or view top-rated stocks.

What is Harrow Health's stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Harrow Health's stock. Their HROW share price forecasts range from $22.00 to $37.00. On average, they expect the company's share price to reach $30.47 in the next year. This suggests a possible upside of 55.8% from the stock's current price.
View analysts price targets for HROW
or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2023?

Harrow Health's stock was trading at $14.76 at the start of the year. Since then, HROW stock has increased by 32.5% and is now trading at $19.56.
View the best growth stocks for 2023 here
.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our HROW earnings forecast
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings data on Thursday, March, 23rd. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.22. The firm had revenue of $20.33 million for the quarter, compared to analyst estimates of $23.26 million. Harrow Health had a negative net margin of 19.76% and a negative trailing twelve-month return on equity of 1.57%.

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$143.00 million, compared to the consensus revenue estimate of $137.06 million.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Braidwell LP (4.82%), Private Capital Management LLC (3.87%), Portolan Capital Management LLC (3.56%), Renaissance Technologies LLC (3.20%), Assenagon Asset Management S.A. (2.68%) and BlackRock Inc. (1.65%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends
.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $19.56.

How much money does Harrow Health make?

Harrow Health (NASDAQ:HROW) has a market capitalization of $589.15 million and generates $88.60 million in revenue each year. The company earns $-14,090,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Harrow Health have?

The company employs 182 workers across the globe.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745.

This page (NASDAQ:HROW) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -